BOULDER, Colo., July 18 /PRNewswire-FirstCall/ -- Pharmion Corporation will announce its second quarter 2006 financial results on Tuesday, July 25, 2006, before the open of the U.S. financial markets. Pharmion’s senior management will host a conference call and live audio webcast to discuss the company’s results in greater detail at 8:30 a.m. ET on Tuesday, July 25, 2006.
This call is being webcast by Thomson/CCBN and can be accessed at Pharmion’s website at www.pharmion.com.
The webcast is also being distributed over Thomson/CCBN’s Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through Thomson/CCBN’s individual investor center at www.fulldisclosure.com or by visiting any of the investor sites in Thomson/CCBN’s Individual Investor Network. Institutional investors can access the call via Thomson/CCBN’s password-protected event management site, Street Events (www.streetevents.com).
Pharmion is a biotechnology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world’s first approved epigenetic cancer therapy, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company’s website at www.pharmion.com.
Pharmion Corporation
CONTACT: Breanna Burkart or Anna Sussman, Directors, Investor Relationsand Corporate Communications, both of of Pharmion Corporation,+1-720-564-9150
Web site: http://www.pharmion.com/
